The redox switch that regulates molecular chaperones by Conway, Myra E. & Lee, Christopher
BioMol Concepts 2015; 6(4): 269–284
*Corresponding author: Myra E. Conway, Department of Applied 
Sciences, University of the West of England, Coldharbour Lane, 
Bristol BS16 1QY, UK, e-mail: myra.conway@uwe.ac.uk
Christopher Lee: Department of Applied Sciences, University of the 
West of England, Coldharbour Lane, Bristol BS16 1QY, UK
Review
Myra E. Conway* and Christopher Lee
The redox switch that regulates molecular 
chaperones
DOI 10.1515/bmc-2015-0015
Received May 18, 2015; accepted July 10, 2015
Abstract: Modification of reactive cysteine residues plays 
an integral role in redox-regulated reactions. Oxidation of 
thiolate anions to sulphenic acid can result in disulphide 
bond formation, or overoxidation to sulphonic acid, rep-
resenting reversible and irreversible endpoints of cysteine 
oxidation, respectively. The antioxidant systems of the 
cell, including the thioredoxin and glutaredoxin systems, 
aim to prevent these higher and irreversible oxidation 
states. This is important as these redox transitions have 
numerous roles in regulating the structure/function rela-
tionship of proteins. Proteins with redox-active switches 
as described for peroxiredoxin (Prx) and protein disul-
phide isomerase (PDI) can undergo dynamic structural 
rearrangement resulting in a gain of function. For Prx, 
transition from cysteine sulphenic acid to sulphinic acid 
is described as an adaptive response during increased 
cellular stress causing Prx to form higher molecular 
weight aggregates, switching its role from antioxidant 
to molecular chaperone. Evidence in support of PDI as 
a redox-regulated chaperone is also gaining impetus, 
where oxidation of the redox-active CXXC regions causes 
a structural change, exposing its hydrophobic region, 
facilitating polypeptide folding. In this review, we will 
focus on these two chaperones that are directly regulated 
through thiol-disulphide exchange and detail how these 
redox-induced switches allow for dual activity. Moreover, 
we will introduce a new role for a metabolic protein, the 
branched-chain aminotransferase, and discuss how it 
shares common mechanistic features with these well-doc-
umented chaperones. Together, the physiological impor-
tance of the redox regulation of these proteins under 
pathological conditions such as Alzheimer’s disease, 
Parkinson’s disease, and amyotrophic lateral sclerosis 
will be discussed to illustrate the impact and importance 
of correct folding and chaperone-mediated activity.
Keywords: CXXC motifs; human branched-chain ami-
notransferase protein; molecular chaperones; neurode-
generation; peroxiredoxins; protein disulphide isomerase; 
protein folding; S-nitrosylation.
Introduction
The endoplasmic reticulum (ER) hosts a network of highly 
regulated mechanisms governed by molecular chaperones 
and folding enzymes that facilitate the translation and 
correct folding of proteins. The quality control systems of 
the ER ensures that only proteins that are correctly folded 
are selected to be released to the Golgi, whereas misfolded 
proteins are retained for further processing and ultimately 
degraded. These pathways can be controlled through 
changes in the redox environment, where the role of 
protein thiol-disulphide exchange in regulating and direct-
ing protein function is of particular interest (1–3). Redox-
sensitive proteins can be modified by reactive oxygen or 
reactive nitrogen species (ROS/RNS) to higher oxidation 
states resulting in a loss or gain of function. Generation of 
excess ROS/RNS leading to these higher oxidation states 
is balanced by antioxidants such as glutathione and cel-
lular reducing systems, including the thioredoxin and 
glutaredoxin systems (2, 3). In health, the redox potential 
of the cytoplasm favours an overall reduced environment, 
amenable to optimal cell function. However, under con-
ditions where the generation of ROS or RNS exceeds the 
capacity of these reducing systems, damage to cellular 
macromolecules such as DNA, lipids, and proteins occur 
(4–6). A further consequence of increased cellular stress 
is a build-up of misfolded proteins that triggers an inte-
grated protective cellular response.
The molecular chaperones are the first to respond to 
increased immature or misfolded proteins, and function to 
repair them or degrade those that cannot be rescued. This 
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response involves the upregulation of molecular chaper-
ones such as the heat shock proteins (Hsps) (including 
the foldases and holdases) that prevent protein aggrega-
tion. This is termed the unfolded protein response, which 
either refold unfolded proteins or direct them for degrada-
tion through the ubiquitin proteasome or the autophagy 
lysosome system. This is followed by ER-associated deg-
radation (ERAD), which specifically recognises terminally 
misfolded proteins. The ER stress response also includes 
the upregulation of protein disulphide isomerase (PDI) 
and glucose-regulated protein, which act as cellular 
 protectors by alleviating the concentration of misfolded 
proteins. More recently, it has emerged that PDI and other 
enzymes such as the peroxiredoxins (Prxs) are directly 
regulated through changes in the redox environment 
and function as molecular chaperones to prevent protein 
aggregation. Modification of the redox-active thiols of Prx 
to sulphinic acid imposes structural rearrangements that 
trigger a switch from their enzymatic role to their role as 
a molecular chaperone. This nano-switch function may 
also explain the ability of the human branched-chain ami-
notransferase (hBCAT) protein to operate as a transami-
nase under reducing conditions but as an oxidoreductase 
when the environment becomes more oxidising. In this 
review, we will focus on these select redox-regulated 
chaperones including the Prxs, PDI, and the metabolic 
protein the hBCAT. We will conclude with an overview of 
their associated roles with neurodegenerative conditions 
such as Alzheimer’s disease (AD) and amyotrophic lateral 
sclerosis (ALS).
Redox regulation: thiol-disulphide 
exchange
Modifications of redox-sensitive cysteine 
residues
The most common types of ROS/RNS and their derivatives 
include the hydroxyl radical (·OH), hydrogen peroxide 
(H2O2), the superoxide anion (O2-), singlet oxygen (1O2), 
peroxynitrite (ONOO-), and nitric oxide (NO). At low con-
centrations, these species play roles as secondary mes-
sengers in the regulation of intracellular cell signalling, 
important for normal cell function. However, generation 
of excess cellular stress will damage cellular macromole-
cules  (4–6). The most common target in proteins are redox-
sensitive cysteine residues, particularly those present in 
CXXC motifs (7, 8). These thiol-centred motifs operate as 
redox switches that facilitate the reversible regulation of 
proteins. Reactivity of these cysteines is dependent on 
their local microenvironment and their overall pKa, where 
a low pKa results in deprotonation generating a reactive 
thiolate anion (R-S-). In general, the cysteine residue 
closest to the N-terminus of a protein is the nucleophilic 
thiolate anion with the lower pKa and is typically found 
at the end of α-helical structures (9). The redox potential 
is also dictated by the amino acids that are flanked by the 
reactive thiols. Oxidation of thiolate anions first gener-
ates a cysteine sulphenic acid [Figure 1A (i)], which can be 
identified using chemical-specific probes such as dime-
done or with mass spectrometry (10). Cysteine sulphenic 
acids are considered highly unstable transient intermedi-
ates with a propensity to form more stable associations 
with other accessible cysteine residues. The potential out-
comes will dictate if the reaction is reversible (e.g. disul-
phide bond) or irreversible (e.g. sulphinamide). The most 
notable is the formation of either inter- or intra-disulphide 
bonds [Figure 1A (ii and iii)]. Disulphide bond formation 
allows proteins to cycle between their active and inactive 
forms, creating a regulatory control switch (2, 11). The 
generation of mixed disulphides with glutathione, termed 
S-glutathionylation, also favours reversible regulation 
[Figure 1A (iv)]. Sulphenic acids can also react with amino 
groups forming sulphonamides. These oxidation products 
can be reversed by members of the thioredoxin or glu-
taredoxin systems [Figure 1A (v and vi)] or through non-
enzymatic reactions with glutathione or vitamin C (2, 3, 
12). If  oxidation of the cysteine sulphenic acid proceeds to 
sulphinic or sulphonic acid or sulphinamide, the reaction 
is irreversible (Figure 1B). However, there is one known 
exception where oxidation to sulphinic acid is reversible, 
i.e. eukaryotic Prx. Here, the sulphinic acid form can be 
reduced by sulphiredoxin (Srx), offering a novel regula-
tory mechanism for overoxidised reactions (13, 14).
Oxidoreductase systems
For reversible regulation of intra- and intermolecu-
lar as well as mixed disulphide bonds to occur, the cell 
must express oxidoreductase systems. Two of the most 
described reducing systems in the cell are the thioredoxin 
and glutaredoxin systems, characterised by their redox-
active CXXC motifs and typical thioredoxin structural fold 
(15). These systems maintain the redox state of the cell 
and are induced under oxidative stress. The thioredoxin 
system is composed of thioredoxin (Trx), thioredoxin 
reductase (TR), and NADPH. There are two isozymes of 
Trx: cytosolic Trx 1 and mitochondrial Trx 2. The redox 
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potential for human Trx is -230  mV and is believed to 
remain 90% reduced in healthy cells (16). Reduction of 
protein disulphide bonds is initiated through the nucleo-
philic attack of the reactive cysteine of Trx, which has a 
low pKa, resulting in formation of a mixed disulphide bond 
(17) [Figure 1 (vi)]. The reduced protein is subsequently 
released by the interaction of the N-terminal cysteine of 
the -CGPC- motif of Trx forming an intra-disulphide bond. 
Reduced Trx is then regenerated through redox cycling 
with TrxR and the reducing equivalent NADPH. The glu-
taredoxin system has a similar composition including 
NADPH, glutathione reductase (GR), glutathione (GSH), 
and glutaredoxin (Grx). Glutaredoxin has a dithiol and 
monothiol form characterised by a -C-P-Y-C- and -C-G-F-S- 
motif, respectively (15). Dithiol Grx is a general thiol-disul-
phide oxidoreductase, which utilise GSH and operate in 
a series of thiol exchange reactions producing GSSG, 
that is subsequently reduced by an NADPH-dependent 
GSH reductase [(i) (GR) R-S2+Grx-(SH)2→R-(SH)2+Grx-S2; 
(ii) Grx-S2+2GSH→Grx-(SH)2+GSSG] (15). The monothiol 
Grx system preferentially reduces proteins that are S-glu-
tathionylated, but can also reduce mixed disulphides 
Figure 1: Redox regulation of thiol oxidation.
(A) (i) Oxidation of a thiolate anion generates a cysteine sulphenic acid. (ii) Thiols that are structurally within 3 Å, often in a -CXXC- motif, 
can form intramolecular disulphide bonds or (iii) intermolecular disulphide bonds with other protein thiols (iv). The generation of mixed 
disulphides for example with glutathione, termed S-glutathionylation, favours reversible regulation. These oxidation products can be 
reversed by members of the thioredoxin (Trx) or glutaredoxin (Grx) systems. (v) Reduction of protein disulphide bonds is initiated through 
the nucleophilic attack of the reactive cysteine of Trx, resulting in the formation of a mixed disulphide bond, subsequently releasing the 
reduced protein. Reduced Trx is regenerated through redox cycling with thioredoxin reductase (TrxR) and NADPH. (vi) The Grx system 
utilises glutathione (GSH) and operates in a series of thiol exchange reactions producing GSSG that is subsequently reduced by an NADPH-
dependent GSH reductase. (B) Sequential oxidation of cysteine sulphenic acid results in the formation of sulphinic or sulphonic acid.
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[R-S-SG+Grx-(SH)2→R-SH+Grx-S-SG]. Here, the mixed 
disulphide substrate is reduced by Grx forming Grx-SSG 
[Figure 1 (vi)]. Grx-SSG is subsequently reduced with GSH, 
which becomes oxidised, producing GSSG in the reac-
tion [Grx-S-SG+GSH→Grx-(SH)2+GSSG]. Levels of GSH are 
maintained through the NADPH-dependent GR (Figure 1). 
The true importance of these systems is as gatekeepers of 
cellular redox status, preventing higher and typically irre-
versible modifications. Throughout this review, we will 
focus on how these redox regulatory systems play more 
intricate roles, where enzymes share dual roles and switch 
between functions depending on the redox state.
Molecular chaperones
Molecular chaperones can be categorised into two main 
groups based on their dependence on ATP: the foldases 
(e.g. Hsp60) are ATP dependent and the holdases (e.g. 
HspB1–10) are independent of ATP (18). The Hsps are 
ubiquitously expressed in all cells and in all subcellu-
lar compartments. They function through hydrophobic 
interactions with unfolded/misfolded proteins, forming 
intermediates that prevent protein aggregation (19, 20). 
Molecular chaperones also rearrange proteins within more 
complex protein structures such as oligomers, translocate 
proteins in and out of organelles, and assist in the turno-
ver of proteins tagged for degradation (21). Although their 
expression is characteristically linked with induction by 
stress such as heat-shock or hypoxia, they also play a role 
in protein stabilisation under non-stress conditions.
Heat shock proteins: ATP-dependent 
foldases
The foldases represent the more characterised families of 
Hsp, including Hsp60, Hsp70, Hsp90, and Hsp100. Here, 
the binding and hydrolysis of ATP facilitates a change in 
substrate affinity between the chaperone and the unfolded 
protein, preventing unfavourable molecular interactions 
such as aggregation, promoting correct folding. The sub-
strate may need to undergo several sequential rounds of 
binding and release to attain the ultimate correctly folded 
state. The foldases, such as the Hsp70 family, have an 
ATPase domain (N-terminal) and a C-terminal substrate-
binding domain that undergo an orchestrated conforma-
tional change to facilitate their functional role, which also 
depends on their interaction with other chaperones such 
as Hsp40 (also known as the J protein) (Figure 2A) (22). This 
is initiated through ATP binding, which opens the helical 
Figure 2: Chaperone activity and regulation of HSP70.
(A) Substrate is directed to HSP70 by HSP40 when ATP is bound. 
On ATP hydrolysis, the helical lid closes, stabilizing the substrate-
Hsp70 complex. NEFs regulate substrate binding and release by 
supporting the exchange of ADP for ATP. Peptides may undergo 
several rounds of refolding, before their correct folded state is 
achieved, preventing aggregation. (B) An increase in ROS triggers 
the binding of unfolded proteins to HSP70, which releases the 
HSFs. These proteins are directed to the nucleus where they are 
hyperphosphorylated and form trimers. Binding of HSF1 to HSE 
results in the increased transcription of molecular chaperones.
lid, exposing the substrate (unfolded protein) binding 
site. Together with Hsp40, the substrate is recruited, but 
only when ATP hydrolysis occurs and the helical lid closes 
is the substrate-Hsp70 complex stabilised. Peptides may 
undergo several rounds of refolding, where binding and 
release is rapid but controlled, until their correct folded 
state is achieved, preventing aggregation. In addition to 
Hsp40, co-factors such as the nucleotide exchange factors 
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(NEFs) regulate binding and release, where NEFs reinitiate 
the Hsp70 cycle by supporting ADP release and rebinding 
of ATP (23). Hsp70 also interacts with Hsp100 in disag-
gregating large aggregates (24). During oxidative stress, 
cellular levels of ATP rapidly decrease (24–26), which will 
impact the function of the foldases, leading to misfolding 
and aggregation of proteins. This is where the holdases 
are particularly important as they can bind to the hydro-
phobic regions of misfolded proteins, preventing aggrega-
tion without the need for ATP.
Heat-shock proteins: ATP-independent 
holdases
The holdases are small Hsp (sHsp, approximately 
10–40  kDa), composed of 10 members (HspB1–10) that 
regulate proteome stability in an ATP-independent 
manner and expressed under stress (18, 27–29). Although 
the sHsps have widespread heterogeneity, they share 
common properties, including structural motifs with a 
conserved α-crystallin domain that permits dimerisation 
and the ability to form oligomers (30). A conserved triad 
motif (Ile-Xaa-IIe/Val), in most but not all sHsp, is linked 
to the oligomerisation of these sHsps, which change in 
size and organisation dependent on their substrates or 
stress indicator (31). Their major role is to prevent aggre-
gation of partially misfolded proteins and function as a 
‘docking’ station that sequesters the non-native proteins 
prior to refolding by other chaperones such as Hsp70 or 
Hsp100. This ability to form oligomers is also shared by 
the Prxs, discussed later in this review. The holdases also 
interact with the cytoskeletal system, which provides scaf-
folds to prevent aggregation of misfolded proteins (32).
Indirect redox regulation of molecular 
chaperones
The chaperones are tightly regulated at both the tran-
scriptional and translational levels. Although not directly 
redox regulated at the protein level, the genes of these 
chaperones are controlled through transcription factors 
called heat shock factors (HSFs), which are induced 
through oxidative stress (Figure 2B) (33). In mammals, 
there are four HSFs, with HSF1 predominantly expressed. 
In response to increased cellular stress, HSF1 binds to a 
consensus heat shock element (HSE) within the promoter 
region of HSF1, resulting in increased gene expression of 
HSP. Under normal physiological conditions, HSF1 is inac-
tive, does not bind to DNA, but is reported as bound to 
chaperones such as HSP70 or HSP90. An increase in cel-
lular ROS or heat shock causes the chaperone complex to 
bind the unfolded proteins, releasing HSF1. In a series of 
reactions that involves hyperphosphorylation, trimerisa-
tion, and redistribution to the nucleus, HSF1 binds to the 
HSE upregulating these chaperones (Figure 2B) (34). The 
rate-limiting step to this reaction is the binding of chap-
erones such as Hsp70, which renders the HSF inactive, 
attenuating the response (33). There are, however, excep-
tional examples where chaperones are directly regulated 
through changes in their redox environment, including 





Peroxiredoxins are primarily classed as antioxidants 
that reduce hydrogen peroxide, peroxynitrite, and alkyl 
hydroperoxides (35). The rate of Prx-mediated detoxifica-
tion of hydrogen peroxide is lower (1 × 105 M-1 s-1) relative to 
other antioxidants such as catalase (1 × 106 M-1 s-1), and Prx 
appears to be highly sensitive to overoxidation leading to 
inactivation (27). Overoxidation to higher oxidation states 
has, however, assigned a novel role for Prx in chaperone-
mediated activity, but the physiological importance still 
remains to be fully characterised. There are six isoforms of 
Prxs (PrxI–VI), which show cell and tissue specificity (36). 
Based on the role of cysteinyl residues involved in cataly-
sis, the Prx are classified into two categories: the 1-Cys and 
2-Cys Prx – the latter is further subdivided into ‘typical’ and 
‘atypical’ 2-Cys Prxs (37). Common to all Prx is a conserved 
N-terminal active-site cysteine (termed the peroxidatic 
cysteine, Cp), where the substrate (e.g. hydrogen peroxide) 
is reduced through a sulphenic acid intermediate (35–37). 
It is the second step, disulphide bond formation, which 
differentiates between categories. Important to this review 
is the ‘typical’ 2-Cys Prx (T2-CP), where the N- and C-ter-
minal redox-active cysteine residues are conserved (Figure 
3). The N-terminal residue is typically at position 51 and 
the C-terminal residue at position 171. T2-CP operates as 
a homodimer with a catalytic active site in each subunit. 
In T2-CP, once Cys51 is oxidised, the resolving cysteine 
at position 171, located on the other subunit, reduces the 
N-terminal oxidised thiol, in a top to tail arrangement (38, 
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39). The two molecules are bound together by inter-subunit 
disulphide bond formation, which is then reduced by oxi-
doreductases, such as the Trx system, recycling the protein 
(40) (Figure 3). For ‘atypical’ Prx (e.g. PrxV), although two 
cysteines are also required for catalysis, and the endpoint, 
resulting in the recycling of thiols by Trx, is the same as 
described for T2-CP, the resolving cysteine is located in 
the same subunit as the N-terminal cysteine, resulting in 
the formation of an intra-molecular disulphide bond (37). 
In the case of 1-Cys Prx (e.g. Prx VI), only the N-terminal 
cysteine is required for catalysis and substrate release is 
thought to be regenerated through vitamin C or low molec-
ular weight (LMW) thiols (27).
Peroxide-induced conformational change for Prx, insight 
into dual role
As with all proteins, conformational change and struc-
tural dynamics strongly influence catalysis and function. 
When reduced, T2-CP is fully folded and the reactive thiols 
are substantially distant ( ≥ 13 Å apart), not to mention the 
fact that they are on opposite subunits, with the resolving 
cysteine partially buried (38). Thus, for catalysis, partial 
protein unfolding of the active site to expose the reactive 
thiol is required, and it remains in this form until the thiols 
are recycled by Trx. The rate at which unfolding occurs is 
delayed by a C-terminal extension, which can result in 
the overoxidation of the N-terminal cysteine, in particular 
under oxidative stress, which will impact its antioxidant 
activity (see below). However, as the sulphinic acid form 
of Prx could be reversed by Srx, it provided the scope for 
this reaction to have dual mechanistic roles (41, 39, 42). A 
key factor to emerge was the ability of Prx to adopt several 
structural conformations, including oligomerisation, 
dependent on the redox environment.
Its role as a redox chaperone was first described in 
yeast where two cytosolic isoforms of Prx were shown 
to alternate their function between an antioxidant and a 
molecular chaperone, dependent on the redox environ-
ment (43). Under normal physiological conditions, where 
low levels of ROS are generated, Prx forms LMW structures 
such as dimer, tetramer, and oligomer conformations. 
Under these conditions, peroxidase activity predominates 
(Figure 4). However, when cellular stress increases, medi-
ated through heat shock or increased ROS, higher molec-
ular weight (HMW) structures accumulate (Figure  4). 
Notably, as described above, the reactive  N-terminal 
cysteine becomes overoxidised to sulphinic acid, trig-
gering the chaperone activity of yeast Prx. Moreover, the 
C-terminal contains a -GGLG- loop and an additional 
 α-helix with a conserved YF domain that cover the active 
site when T2-CP is reduced. This additional  C-terminal 
extension confers structural stability to the reactive 
cysteine and appears to slow transition to disulphide bond 
formation, rendering the Cp-sulphenic acid susceptible to 
further oxidation to sulphinic acid formation (44). In vitro 
studies have indicated that these structural transitions of 
Figure 3: Antioxidant activity of typical 2-Cys peroxiredoxin.
Reduction of hydrogen peroxide occurs through a sulphenic acid intermediate forming an intermolecular disulphide bond with the resolv-
ing cysteine of the -CXXC- motif on the other subunit. The disulphide bond is then reduced by the Trx system, using NADPH as a cofactor, 
recycling the protein.
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Prx prevent protein aggregation of unfolded proteins gen-
erated in response to heat shock (45). Thus, overoxidation 
of its reactive thiol to a sulphinic acid creates a nanoswitch 
regulating the proteins’ chaperone activity but only when 
extreme ROS occurs. This type of regulation could prevent 
T2-CP interfering with the chaperone foldases under mild 
oxidative stress when ATP is available, preventing little 
crossover and promoting efficient folding. It has also been 
proposed as an adaptive response to increased ROS, where 
more potent antioxidants, such as catalase, take over this 
role in the cell (45, 46).
Protein disulphide isomerase
PDI: thiol disulphide exchange
PDIs (EC 5.3.4.1), part of the thioredoxin superfamily, pri-
marily reside in the ER and operate in the maturation, trans-
port, and folding of secretory proteins (47). These enzymes 
catalyse the oxidation, reduction, and isomerisation of 
disulphide bonds, whereas molecular chaperones mediate 
correct protein folding and stabilise structures, yet do not 
increase the rate of protein folding like the isomerases (18, 
21). These oxidoreductase proteins also operate as chaper-
ones in polypeptide refolding, involving redox-dependent 
and -independent reactions (27). Like Trx and Grx, the PDI 
family have characteristic thioredoxin-like fold structures 
with most including one to three redox-active CXXC motifs 
(48). In human PDI (hPDI) and yeast, there are four thiore-
doxin-like domains (a, a’, b, and b’). Structurally, these are 
arranged in a ‘U-shaped’ assembly where the a/a’ domains 
face each other, each containing a solvent-exposed cata-
lytic redox-active -CGHC- motif (49), where the thiols can 
cycle between an intramolecular disulphide bond or a 
reduced state and are responsible for the thiol-disulphide 
isomerase activity of PDI. As an oxidoreductase, oxidised 
PDI transfers its electrons to reduced substrates, forming a 
mixed disulphide. Reoxidation of the PDI a domain occurs 
through the nucleophilic attack of the reactive thiols of the 
structurally opposing a’ domain. This reaction is catalysed 
by Ero1, which is responsible for the transfer of oxidising 
equivalents to PDI, where electrons are ultimately chan-
nelled to molecular oxygen (reviewed in Ref. 19). PDI, in 
its reduced form, targets its substrate disulphide through 
a nucleophilic attack and the resulting mixed disulphide 
is resolved with the free thiol group, oxidising PDI. As an 
Figure 4: The redox nano-switch of ‘typical’ 2-Cys peroxiredoxin.
The antioxidant activity of T2 CP is considered to predominate when levels of ROS are low. However, an increase in cellular stress creates 
HMW structures, where T2 CP switches its role from antioxidant to chaperone, stabilizing unfolded proteins. This switch is believed to be 
regulated through overoxidation to sulphinic acid, which can be reversed by sulphiredoxin, regenerating reduced T2 CP.
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isomerase, the mechanistic details are not entirely eluci-
dated; however, a sequence of thiol/disulphide exchange 
reactions occur that rearrange the pattern of disulphide 
bonds, generating the correctly folded protein. Substrate 
specificity is considered to be governed by the highly 
hydrophobic b domains, which are flanked by the a and 
a’ domains. The a’ and b’ domains are connected through 
a 19-amino-acid inter-domain link, called the x-linker, 
which is predicted to promote flexibility, influencing sub-
strate binding (50). Another key feature is the highly acidic 
C-terminus, which is involved in calcium binding and con-
tains the ER-retrieval motif KDEL.
PDI: redox-independent chaperone activity
The binding of polypeptides (10–15 amino acids in length) 
to PDI has more often been associated with the hydro-
phobic b domains, independent of redox regulation (51). 
However, for full-length proteins, a larger proportion of 
PDI is required (52). In vitro experiments demonstrated 
that PDI had chaperone-mediated activity with glyceral-
dehyde dehydrogenase and rhodanase, respectively, pro-
teins without disulphide bonds (53, 54). Chaperone activity 
in addition to isomerase activity is required for maximal 
refolding and reactivation of reduced/ denatured acidic 
phospholipase A2 (55). Physiologically, a chaperone-
mediated role for PDI has also been assigned in the ERAD 
response, and in its ability to enhance tissue factor coag-
ulant activity on microvesicles (56, 57). Binding of ERE-
containing DNA to the oestrogen receptor was recently 
reported to be enhanced by PDI, independent of its isomer-
ase activity, as evidenced by the ability of the -CGHC- site-
directed mutants to also promote binding (58). Also, PDILT, 
a PDI homolog, without a redox-active -CGHC-, was shown 
to display chaperone activity, when found to interact with 
somatostatin (59). In these examples, the activity of the 
thioredoxin domains is not required and the chaperone 
activity is independent of the redox environment.
PDI: redox-dependent chaperone activity
The first evidence in support of a redox-regulated chap-
erone mechanism originated from work with cholera 
toxin (60, 61). Cholera toxin consists of A and B subunits, 
where only a fragment of the A subunit, A1, is active and is 
released into the cytosol. For this to occur, the toxin must 
first make its way to the ER, where it is initially nicked by 
proteases to undergo unfolding, a step required to release 
the A1 segment. Here, the hydrophobic segments of the 
A1 chain are exposed and present as a substrate for PDI, 
which must be reduced for binding to occur and on oxida-
tion is released, unfolding the protein (60). The authors of 
this study emphasised that the redox cycling was not from 
the cysteines in the substrates but most certainly from 
PDI. Building on these studies, the authors showed that 
the latter oxidation reaction is catalysed by Ero1, releas-
ing the A1 chain. Release of the A1 chain to a protein at 
the luminal side of the ER completes the chaperone role 
of PDI (61). This mechanism of action was compared with 
the ATP-driven chaperone activity of Hsp70, where a con-
formational change, causing an opening and closing of 
the chaperone-binding site, regulates folding. However, in 
this instance, the ATP/ADP regulatory switch is replaced 
by the reactive thiols. Similarly, in bacteria, Hsp33, which 
protects bacteria against oxidative stress, has also been 
identified as a redox-dependent chaperone (27). PDI was 
also shown to associate with NAD(P)H oxidase, a promi-
nent source of ROS in the vasculature (62). In neutrophils, 
NAD(P)H oxidase activity was regulated through redox-
chaperone PDI activity. Here, using colocalisation and 
pull-down assays, PDI associated with distinct subunits of 
the oxidase complex. The authors proposed that both redox 
and non-redox interactions with p47phos contribute to a role 
for PDI as a ‘NADPH oxidase complex organiser protein’, 
indicating a novel role for PDI in oxidase  regulation (63).
Although the concept of PDI as a redox-regulated 
chaperone was challenged at the time, largely because 
this redox-regulated chaperone function could not be 
repeated for other proteins (64), the elucidation of the 3D 
structure of PDI in its reduced and oxidised form now pro-
vides strong evidence in support of this mechanism (49, 63, 
62). Initial studies by Tsai et al. in 2001 showed that PDI 
adopted a more compact structure in the reduced form. 
In the reduced and oxidised forms, a conformational shift 
induced by oxidation of the -CGHC- motif of the a’ subunit 
created a change in the rotation of the C-terminal of the 
x-linker, exposing a greater surface area of the hydro-
phobic area of the b’ domain (Figure 5) (49). When oxi-
dised, the distance between the two active -CGHC- regions 
increases by 12.7 Å. This more open structure promotes the 
binding of unfolded peptides, where high binding affin-
ity is gained. Now PDI can oxidise the substrate, where 
PDI itself becomes reduced and the structural conforma-
tion becomes more compact. Once correctly folded, the 
substrate is released. Reported by several groups, homo-
dimerisation of the bb’ domain, regulated by the x-linker 
region, is suggested to block substrate access, regulat-
ing PDI activity (65–67). Molecular dynamic simulation 
of three-dimensional structures suggested that in solu-
tion, hPDI may adopt more rigid structures facilitated 
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by inter-domain salt bridges, encouraging inter-domain 
disulphide bond formation, where a role for domain a was 
also supported (68). Clearly, these proteins are more than 
just an oxidoreductase and also operate as chaperones in 
polypeptide refolding, where evidence in support of redox-
dependent and -independent reactions exists, indicating 
that changes in the redox environment linked to changes 
in the structural dynamics may direct substrate specificity 
under normal and pathophysiological conditions.
Metabolic redox chaperones: the 
hBCAT proteins
Transamination and redox regulation
The hBCAT proteins are PLP-dependent aminotransferases, 
where transamination consists of the coupled half-reaction 
in which the PLP cofactor transfers between its PLP and 
pyridoxamine (PMP) form via a Ping-Pong Bi-Bi mecha-
nism (69, 70). These proteins have a mitochondrial (m) 
and cytosolic (c) isoform with tissue-specific locations, 
with hBCATm, the most ubiquitous isoform, thought to be 
responsible for the majority of transamination outside the 
central nervous system with the highest levels of hBCATm 
recorded in the pancreas, kidney, stomach, and brain (70). 
hBCATc, is largely associated with neuronal cells and is pre-
dominantly found in the soma and proximal dendrites of 
glutamatergic and GABAergic neuronal cells, supporting its 
role in contributing to both the storage and metabolic pools 
of the neurotransmitter glutamate and as the precursor for 
GABA production in GABAergic neurons  (71–73). Although 
hBCATm is ubiquitously expressed throughout the body, 
there is extensive immuno-positive staining for hBCATm 
specific to brain vasculature, indicating a new role for 
hBCATm in brain glutamate regulation (71, 74). BCAT cata-
lyse the transfer of the α-amino group from the hydrophobic 
branched-chain amino acids (BCAAs) leucine, isoleucine, 
and valine, to α-ketoglutarate releasing their respective 
keto acids, ketoisocaproate, keto methyl valerate, and keto-
isovaline and glutamate, regenerating the enzyme (75, 76). 
The committed step in BCAA oxidation is catalysed by the 
second enzyme in the catabolic pathway, the branched-
chain  α-keto acid dehydrogenase complex (BCKDC). The 
enzyme complex catalyses multistep reactions that lead to 
the irreversible oxidative decarboxylation of the branched-
chain keto acids giving rise to branched-chain acyl-CoAs. 
The BCKDC complex is organised around a 24-meric core 
scaffold consisting of dihydrolipoamide acyltransferase 
(E2) subunits, where multiple copies of the branched-chain 
keto acid dehydrogenase (E1) and dihydrolipoamide dehy-
drogenase (E3) are non-covalently attached.
Leucine -ketoglutarate -ketoacids L-glutamate 
(Scheme 1)
+α α +
Structurally, the BCAT proteins operate as homodi-
mers with each monomer existing as a large and small 
Figure 5: Protein disulphide isomerase as a redox-chaperone.
Oxidation of PDI increases the distance between the two active sites, exposing a larger surface area of the hydrophobic region, promot-
ing the binding of unfolded proteins. Oxidation of the substrate, introducing disulphide bonds, results in the reduction of PDI, where the 
structure now adopts a more compact conformation. Once correctly folded, the substrate is released.
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domain (77, 78). Although they share the same substrate 
specificity, they have subtle catalytic differences and are 
differentially regulated through changes in the redox 
environment, through their peroxide-sensitive redox 
switch, which is ~10 Å from the active site (9, 11, 79–81). 
Through biochemical and X-ray crystallography investiga-
tions, it was determined that reduction and oxidation of 
the -CXXC- motif represented the active and inactive forms 
of the proteins respectively. Using peptide mapping, the 
reactive thiols were identified as -Cys315-XX-Cys318- for 
hBCATm and -Cys335-XX-Cys338- for hBCATc (9, 11). In 
each isoform, the N-terminal cysteine residue is the most 
reactive, sensing changes in the redox environment, 
whereas the C-terminal residue permits reversible regu-
lation through the formation of a disulphide bond via a 
sulphenic acid intermediate (11, 82). ROS-mediated oxi-
dation resulted in the complete reversible inactivation of 
hBCATm, whereas air oxidation alone resulted in a loss of 
40–45% functional activity for hBCATc, with no further 
loss on treatment with hydrogen peroxide (11, 83). X-ray 
crystallography studies and kinetic analysis demon-
strated that the predominant effect of oxidation was on 
the second half-reaction rather than the first half-reaction, 
where disruption of the CXXC centre results in altered sub-
strate orientation and an unprotonated PMP amino group, 
thus rendering the enzyme catalytically inactive (83). The 
reactive cysteines of both isoforms are also targets for 
the S-nitrosylating agent, S-nitroso glutathione (GSNO), 
where a transition between S-nitrosation and S-glutath-
ionylation was reported dependent on the level of RNS 
exposure (81). The glutaredoxin/glutathione system 
reversed this inactive form, supporting a role for hBCAT in 
cellular redox control.
Redox-dependent substrate channelling
A redox-chaperone function of hBCAT has been shown to 
be important for the formation of a metabolon, a supra-
molecular complex, where metabolic enzymes associate, 
to facilitate substrate channelling (84). Here, the physical 
association of hBCATm to the E1 subunit of the BCKDC was 
required for the channelling of the BCKA product to the 
active site of E1. In this instance, mutation of the redox-
active thiols impaired the association of hBCATm with the 
BCKDC, supporting a role for redox signalling in the regu-
lation of this metabolon. As described for PDI, the CXXC 
motif is located at the opening of the active site, where the 
reduced state and the net dipole charge are important for 
complex formation between hBCATm and the E1 complex. 
Oxidation or mutation of the reactive thiols increases the 
net dipole charge, destabilizing the substrate and the PLP 
cofactor, interfering with the metabolon. Several other 
metabolic proteins, isolated from neuronal IMR32 cells, 
were also shown to have peroxide-mediated redox associ-
ations with hBCAT (80). These proteins have either known 
reactive cysteine residues or CXXC motifs with phospho-
rylation sites and/or are directly involved or controlled 
by G-protein cell signalling, known to be modulated by 
peroxide.
The role of hBCAT in protein folding and 
redox-chaperone activity with PDI
More recently, we showed a novel functional role for 
hBCAT in redox protein folding (85). The hBCAT proteins 
were shown to catalyse the refolding of reduced and dena-
tured RNA. As the redox environment became more oxidis-
ing, the oxidase activity of hBCATm continued to increase 
relative to hBCATc. Although both hBCAT proteins had 
thiol isomerase activity, it was 50% less than their oxidase 
activity. Site-directed mutagenesis of the reactive thiols 
of hBCAT showed that during catalysis, the N-terminal 
cysteine is responsible for the first step in forming an 
intermediate with RNase and although the single C-termi-
nal cysteine mutants could form this initial step, substrate 
release was impossible as illustrated by the inability of 
either mutant to catalyse refolding (85). Notably, when 
these proteins were treated with GSNO, HMW structures 
were reported and the rate of refolding increased, a feature 
reported for Prxs when overoxidised. Thus, under reduced 
conditions, the role of hBCAT favours transamination and 
metabolon formation with BCKDC, whereas oxidation 
changes the structural conformation opening the active 
site to novel substrates to promote protein folding and 
chaperone activity, predicted to be supported by its three 
hydrophobic pockets in the active site. Further evidence in 
support of the hBCAT proteins, in particular hBCATm, as a 
redox chaperone was corroborated with findings to show 
that hBCATm colocalised with PDI, in both human brain 
and cell models, indicating that these two proteins were 
interacting. Using confocal and electron microscopy, our 
studies established that the interaction of hBCAT with PDI 
was redox regulated (85). Although hBCAT did not appear 
to impact the overall PDI activity, it did increase the rate of 
refolding. We hypothesised that hBCATm may be a novel 
chaperone for PDI operating through a thiol disulphide 
exchange mechanism or independently as an oxidoreduc-
tase regulated through the redox environment (Figure 6). 
The physiological role of this interaction has not yet been 
elucidated, but new data have isolated a protein-folding 
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 88–90). Triggered by increased ROS/RNS, the holdases 
and foldases respond and try to evoke their chaperone 
activity. However, for reasons not entirely understood, 
they cannot refold these ‘disease’ proteins and are often 
found associated with these aggregates, indicating an 
imbalance between the production and activity of these 
Hsp (91, 92). In neuronal cell models, however, overex-
pression of Hsp70 reduces aggregation, in particular with 
respect to Aβ and τ, aggregates particular to AD,  indicating 
their role as neuroprotectors; however, it remains unclear 
why this does translate to the human brain (93, 94). A 
neuroprotective role has also been assigned for Prx, in 
 particular with respect to resisting neurotoxicity by Aβ 
(95–97). In human brain, isoforms of Prx were found to 
be differentially expressed in AD, Pick’s disease, and 
Down syndrome, indicating that these antioxidants show 
regional brain regulation, in response to increased cel-
lular stress, dependent on the type of neurodegenerative 
condition identified (54). Other conditions where aggre-
gated proteins accumulate such as PD, Creutzfeldt-Jakob 
disease, and ALS also show increased Prx expression 
(98–100). Given the role of Prx as an antioxidant and as a 
redox chaperone, this increased expression should reduce 
the accumulation of misfolded proteins in neurodegener-
ative conditions. However, in reality, aggregates still form; 
therefore, the proposed neuroprotective role is insufficient 
or the activity is compromised through another pathway 
yet to be discovered. Clearly, further studies are required 
to manipulate these pathways and offer insight into why 
these fine-tuned quality control systems lose their neuro-
protective capacity.
A role for PDI in protein misfolding has emerged as a 
key link to understanding how aggregates accumulate in 
the brain, and play a role in the pathogenesis of neuro-
degenerative conditions including AD, PD, Huntington’s 
disease, and ALS (19, 20, 101–106). PDI has been shown 
to accumulate with neurofibrillary tangles and the dys-
trophic neurites of senile plaques in AD brain, and with 
FUS-positive ubiquitinated inclusions in human ALS 
patient spinal cords (107, 108). Not only was there an 
increase in PDI expression in AD, PD, and ALS brain, the 
amount of S-nitrosylated PDI was also substantial (107, 
109–115). S-nitrosylation of PDI, through the redox-active 
thiols of the a and a’ domains, inhibits enzyme activity. 
Cell models of AD pathology show that PDI inactivated 
through NO triggers an accumulation of poly-ubiquitinated 
proteins, an increase in ER stress, and induction of apop-
tosis (92,  99). Similar reports using ALS and PD models 
show that overexpression prevents aggregation, whereas 
inhibition of PDI results in the accumulation of misfolded 
proteins (107, 116–119). Further understanding of these 
metabolon, offering exciting new roles for these metabolic 
proteins as redox chaperones (Lee et  al., unpublished 
observations).
Molecular chaperones and their role 
in neurodegenerative conditions
The cell is equipped to combat an increase in cellular 
stress; however, these ‘quality control systems’ seem 
to become overwhelmed, and under sustained cellular 
stress cell function is compromised. One consequence of 
increased ROS/RNS is the build-up of unfolded proteins 
creating aggregates. Accumulation of these aggregates 
contributes to a cascade of events that ultimately results 
in cell death, implicated in the manifestation of numer-
ous disease conditions, including cancer, cardiovascular 
disease, and neurodegenerative conditions (86, 87, 41, 
Figure 6: Redox activity of the hBCAT.
(A) As an oxidoreductase, hBCAT can catalyse the introduction of 
disulphide bonds, refolding proteins. This reaction is redox regu-
lated. (B) As a chaperone, it is hypothesised that through a thiol 
disulphide exchange mechanism, hBCATm can oxidize PDI, becom-
ing reduced and promoting the refolding of substrate proteins. Of 
note is the increase in rate of refolding when hBCATm is incubated 
with PDI during refolding of reduced denatured RNase.
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pathways will determine if inhibitors of S-nitrosylated PDI 
are therapeutically beneficial or if increased expression 
of PDI will generate unfavourable metabolic reactions, 
attenuating its potential role as a target therapeutic.
The hBCAT proteins have also been implicated in the 
pathogenesis of AD, predicted to be linked more with its 
metabolic function rather than its role in redox regulation 
(120). In brief, a regional increase in hBCATc expression 
in the hippocampal region of AD patients was reported, 
whereas an increase of 160% was reported for hBCATm 
in the frontal and temporal cortex compared to matched 
control brains. Increased hBCATm expression correlated 
with Braak stage, suggesting that the expression of this 
enzyme is directly related to the severity of the disease 
(120). Here, a neuroprotective role was assigned to the 
hBCAT proteins, as neuronal cells were morphologically 
intact, with no evidence of apoptotic features. Increased 
expression of hBCAT would, however, be expected to 
increase the glutamate pool, and sustained release may 
destroy surrounding cells. Thus, their intended role in 
neuroprotection may switch to neurotoxic. Alternatively, 
we can speculate that similar to that described for the 
Prxs, the redox switch of hBCAT may signal a change in 
function from its metabolic role to a role as an oxidore-
ductase or redox chaperone when the redox environment 
becomes more oxidizing.
Conclusion
One of the most intriguing aspects of molecular chaper-
one activity is the extensive structural remodelling that 
is required to correctly fold and translocate proteins. 
The recent advances in our understanding of how these 
structural realignments change in response to the redox 
environment have made it clearer that the function of 
molecular chaperones can be redox-dependent and 
redox-independent. This may allow the cell to operate its 
stress response more efficiently, optimizing its chances 
for survival. However, evidently, this is not enough. 
Despite these elaborate transitions between LMW and 
HMW structures to prevent protein misfolding, protein 
aggregation and accumulation persists and clinically 
presents as inclusions or plaques. A major challenge of 
this work is translating these in vitro studies to under-
stand the complexities of protein folding, in particular 
in the human brain. Future studies need to focus on the 
intricacies of these structural changes and aim to eluci-
date the molecular components of the crosstalk between 
redox signalling and molecular chaperone activity. Lack 
of robust cell/animal models, together with the com-
plexities of brain metabolism, explains the barriers that 
challenge the translation to our in vivo understanding of 
protein misfolding. However, what is clear is that in the 
human brain, these molecular chaperones and folding 
enzymes are upregulated, found to be associated with 
aggregates, and in the case of PDI, show evidence of 
S-nitrosylation, that impacts refolding capacity. Clearly, 
the need exists to continue to understand how these 
mechanisms are regulated, as they present with new 
avenues for therapeutics to target protein aggregation, a 
major clinical need for the treatment of neurodegenera-
tive conditions.
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